Skip to main content
SpringerLink
Log in

Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget’s disease of bone

  • Letter to the Editor
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Maricic M (2010) The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol 29:1079–1084

    Article  PubMed  Google Scholar 

  2. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  3. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 114:999–1007

    Article  CAS  PubMed  Google Scholar 

  4. Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR (2010) Prolonged anti-resorptive activity of zoledronate—a randomized controlled trial. J Bone Miner Res 25:2251–2255

    Article  CAS  PubMed  Google Scholar 

  5. Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR (2009) The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 94:538–544

    Article  CAS  PubMed  Google Scholar 

  6. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908

    Article  CAS  PubMed  Google Scholar 

  7. Merlotti D, Gennari L, Martini G, Valleggi F, De PV, Avanzati A, Nuti R (2007) Comparison of different intravenous bisphosphonate regimens for Paget’s disease of bone. J Bone Miner Res 22:1510–1517

    Article  CAS  PubMed  Google Scholar 

  8. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR (2007) Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 22:142–148

    Article  CAS  PubMed  Google Scholar 

  9. Reid IR, Lyles K, Su G et al (2009) Long-term efficacy of zoledronic acid compared with risedronate in Paget’s disease. J Bone Miner Res 24:S358–S358

    Google Scholar 

  10. Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M (2008) Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget’s disease of bone. J Bone Miner Metab 26:635–641

    Article  CAS  PubMed  Google Scholar 

  11. Polyzos SA, Anastasilakis AD, Efstathiadou Z, Kita M, Litsas I, Avramidis A, Arsos G, Moralidis E, Gerou S, Pavlidou V, Papatheodorou A, Terpos E (2009) The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget’s disease of bone. Horm Metab Res 41:846–850

    Article  CAS  PubMed  Google Scholar 

  12. Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S (2008) Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club. Osteoporos Int 19:1109–1117

    Article  PubMed  Google Scholar 

  13. Ralston SH, Langston AL, Reid IR (2008) Pathogenesis and management of Paget’s disease of bone. Lancet 372:155–163

    Article  CAS  PubMed  Google Scholar 

  14. Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH (2010) Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J Bone Miner Res 25:20–31

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 13 Simou Lianidi, 551 34, Thessaloniki, Greece

    Stergios A. Polyzos

Authors
  1. Stergios A. Polyzos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stergios A. Polyzos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Polyzos, S.A. Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget’s disease of bone. Clin Rheumatol 30, 149–150 (2011). https://doi.org/10.1007/s10067-010-1611-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-010-1611-3

Keywords

Search

Navigation